Octapharma

York County Council approved a revised revenue plan for Project Palmetto Rock, a biopharmaceutical company's $1.5 billion facility proposal in Rock Hill. The plan allocates 85% of Rock Hill's tax revenue to schools and 10% of economic development funds annually. Rock Hill City Council will vote on the deal next, which could secure 1,500 jobs but has faced criticism over potential inconsistencies in incentives.

York County's vote on a tax incentive agreement for Octapharma's $1.5 billion U.S. manufacturing project in Rock Hill is stalled due to disputes over cost-sharing between local governments. Rock Hill officials rejected an amended agreement that shifted more financial burden to the city, warning the deal could collapse if the council reaffirms the amendment.

York County and Rock Hill leaders disagree over a tax incentive plan for Octapharma’s US headquarters project. York County’s proposal would require Rock Hill to relinquish 100% of its tax revenue from the company for decades, prompting pushback from the city, which passed a resolution capping tax credits at 50% for the first 10 years. The county will vote on the plan again on July 13.

York County Council approved a tax break amendment for Octapharma’s U.S. headquarters in Rock Hill, reducing the financial burden on local schools from 50% to 31.9% of the tax incentive. The vote passed 5-2, aiming to attract a $1 billion investment and 1,500 jobs while providing Rock Hill Schools with up to $3 million annually in additional revenue.

York County Council approved tax incentives for Octapharma's $1.5 billion project, which includes building a U.S. manufacturing plant and moving its corporate headquarters to York County, creating 1,200 jobs. An amendment adjusted tax revenue shares among local entities, and community reactions included both support and skepticism over tax breaks.

Octapharma, a biopharmaceutical company, may create 1,200 jobs in Rock Hill. Company officials assured the community there is no potential for biohazard or chemical exposure issues.